@johnepm

Gastroenterólogo del Hospital Nacional Guillermo Almenara Irigoyen Lima-Perú. Ex-Presidente de ASPEIN.

 Lima
Joined October 2010
  • Tweets1.3K
  • Following1.9K
  • Followers497
92Media
Buenas tardes estimados amigos. Anunciamos la próxima realización del ECCO Workshop en Lima el 29 de agosto del 2025. Evento organizado por ASPEIN y ECCO. Gracias ⁦⁦@manu_barreiro⁩
3
9
2
33
3,944
Great work by @vipuljairath on Verdict. Does this mean we should no longer take random biopsies for histologic healing? It would certainly be a cost savings! @EdwardLoftus2 @ibddocmaria @Bealoquebea @charlie_lees
5
9
1
60
6,428
Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…

Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the Intern...

Since Selecting Therapeutic Targets in Inflammatory Bowel Disease-II (STRIDE-II), new evidence has become available across inflammatory and patient-centred outcomes. We aimed to update the STRIDE...

thelancet.com
1
3
74
onlinelibrary.wiley.com/doi/…
58
Juan Paredes retweeted
Fernando Gomollón@fgomollonOct 12
Great effort from @geteccu under the extraordinary leadership of @jp_gisbert @maria_chs @EIILaPrincesa finally available in @APandT open-access @aegastro @sepdigestiva
1
8
17
722
Juan Paredes retweeted
Charlie Lees
@charlie_leesOct 11
Replying to @my_ueg
@my_ueg week starts Saturday. My preview is up on Atomic IBD. The hour not to miss is Monday 10:00 in the UEG Forum. VERDICT, then STRIDE-III thirty minutes later. Two answers to the same question. For me the VERDICT question that matters isn't histology against symptoms. It's histology against endoscopy... will the trial have the number of events to answer it? Then FUZION at 48 weeks (how good does it get? will we see a difference between doses?), obefazimod's maintenance data (all eyes on this), PROFILE at five years, and a long list of new molecules (the PDE4s are back). Day-by-day guide in the image. Full preview in the reply.
3
11
4
47
10,971
fg.bmj.com/content/early/202…

Three-year outcomes and alternative diagnoses in FIT-positive symptomatic patients without colore...

Objective Faecal immunochemical testing (FIT) is widely used to triage symptomatic patients for colorectal cancer (CRC), but it is not disease-specific and may reflect a range of alternative bleedi...

fg.bmj.com
1
1
239
Juan Paredes retweeted
Yamile Zabana@yzabanaaOct 3
Llegando al final de mi presidencia en @geteccu: orgullosa, honrada, satisfecha… y profundamente agradecida. En primer lugar, con mi querida junta y después con toda la familia @geteccu. Mi paso por aquí ha sido de las mejores experiencias de mi vida! MUCHÍSIMAS GRACIAS!
10
14
3
75
5,064
Juan Paredes retweeted
Fernando Gomollón@fgomollonOct 3
En cualquier actividad intelectual el buen uso del lenguaje es básico. Es triste constatar cómo lo maltratamos constantemente. Me siento derrotado, pero seguiré en la brecha.
1
3
19
959
GETECCU 2026 llegó a su final. Excelente congreso, excelente presidenta, excelente ambiente y sobre todos excelentes amigos. Con @yzabanaa @manu_barreiro @DanielGinard @pilarnos @anaguticasbas @fgomollon
1
3
16
474
Primer día de GERECCU 2026 con la gran @yzabanaa
1
6
134
watermark02.silverchair.com/…
33
onlinelibrary.wiley.com/doi/…
2
145
Juan Paredes retweeted
Beatriz Gros
@BealoquebeaSep 22
Do not miss our latest publication 🤩📃 Entering the era of disease modification in Crohn’s disease With @LauranneDerikx @NabilQuraishi @JosephHabibi_MD @bribarberio @marie_truyens @nathangrellier5 @EderPiotr @ign76 @sang_hyoung #NuruNoor @Y_ECCO_IBD
27
82
4,038
Juan Paredes retweeted
VoiceForIBD@VoiceForIBDSep 16
Hispanic Heritage Month starts Sept. 15th - Oct. 15th🗓️Being Peruvian 🇵🇪 is an important part of who I am & being a #Latina living with #IBD has shaped how I advocate🥹 That’s one of the reasons I created @VoiceForIBD to make IBD more visible, more understood & more inclusive👊🏼
1
6
217
Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Colonoscopy Intervals and Colorectal Cancer Incidence after Adenoma Removal | NEJM

More evidence is needed to inform recommendations for intervals of colonoscopy surveillance after polyp removal. In this ongoing noninferiority trial conducted in eight European countries, we rando...

nejm.org
4
217
Association Between Bowel Urgency and Intestinal Ultrasound Parameters in Ulcerative Colitis: Insights Into Transmural Inflammation and Symptom Pathophysiology - Serizawa - 2026 - United European Gastroenterology Journal - Wiley Online Library onlinelibrary.wiley.com/doi/…

Association Between Bowel Urgency and Intestinal Ultrasound Parameters in Ulcerative Colitis:...

Background Bowel urgency (BU) is a key symptom of ulcerative colitis (UC), often impairing the quality of life. This study aimed to identify intestinal ultrasound parameters associated with BU,...

onlinelibrary.wiley.com
1
8
258
Association Between Bowel Urgency and Intestinal Ultrasound Parameters in Ulcerative Colitis: Insights Into Transmural Inflammation and Symptom Pathophysiology - Serizawa - 2026 - United European Gastroenterology Journal - Wiley Online Library onlinelibrary.wiley.com/doi/…

Association Between Bowel Urgency and Intestinal Ultrasound Parameters in Ulcerative Colitis:...

Background Bowel urgency (BU) is a key symptom of ulcerative colitis (UC), often impairing the quality of life. This study aimed to identify intestinal ultrasound parameters associated with BU,...

onlinelibrary.wiley.com
8
18
741
Juan Paredes retweeted
Fernando Gomollón@fgomollonSep 11
Replying to @Bealoquebea
To breaking therapeutic ceiling the ONLY realistic tool (for now) is EARLY effective treatment avoiding steroids or strictly limiting its use. New treatments will change and improve in the future, but EARLY is a real key word.
1
4
13
653
Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial - The Lancet Gastroenterology & Hepatology thelancet.com/journals/langa…

Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly...

Early top-down anti-TNF treatment from diagnosis was associated with improved long-term outcomes at 5 years compared with step-up treatment and is suggestive of a disease-modifying effect in Crohn's...

thelancet.com
2
10
331
Juan Paredes retweeted
Beatriz Gros
@BealoquebeaSep 10
There is still significant room for improvement regarding the residual burden of IBD beyond inflammation I am grateful for the opportunity to have collaborated on this publication under @bribarberio leadership with @alex_ford12399 @alearmuzzi @vipuljairath @ibdseb @FernandoMagro6 Edoardo Savarino
Nature Reviews Gastroenterology & Hepatology@NatRevGastroHepSep 9
New online! Beyond inflammation: the residual burden as the next target in inflammatory bowel disease dlvr.it/TVPTqp
1
19
47
4,529
Load more